Editor's note: Details about rilzabrutinib have been corrected in this article. Sanofi's rilzabrutinib performed well in its phase 3 clinical trial, meaning the company can now apply for approval.

Sanofi has reported that the Phase III LUNA 3 trial of rilzabrutinib for the treatment of persistent or chronic immune ...

Sanofi SNY announced that the FDA has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, for the treatment of warm autoimmune hemolytic anemia (wAIHA) and IgG4 ...